Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 50Colorectal Neoplasms 29Prostatic Neoplasms 28Neoplasms 28Breast Neoplasms 27Neoplasm Metastasis 26Multiple Myeloma 24Pancreatic Neoplasms 22Recurrence 18Ovarian Neoplasms 18Squamous Cell Carcinoma of Head and Neck 17Melanoma 17Lymphoma, Non-Hodgkin 17Triple Negative Breast Neoplasms 16Lymphoma, Large B-Cell, Diffuse 15Leukemia, Myeloid, Acute 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Burkitt Lymphoma 14Lung Neoplasms 13Carcinoma, Renal Cell 13Stomach Neoplasms 12Lymphoma, Follicular 12Lymphoma 12Endometrial Neoplasms 12Advanced Solid Tumors 12Small Cell Lung Carcinoma 11Glioblastoma 11Colonic Neoplasms 11Leukemia, Lymphocytic, Chronic, B-Cell 10Uterine Cervical Neoplasms 9

Interventions

peposertib 1avelumab 1Specimen Handling 1Radiation Dose Hypofractionation 1Radiation 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Gallbladder Neoplasms × 30 days × Clear all
NCT04068194 2026-05-13

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
103 enrolled
Gastrointestinal

Gallbladder Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡